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Alterations in the expression of integrin receptors for extracellular matrix (ECM) proteins are strongly
associated with the acquisition of invasive and/or metastatic properties by human cancer cells. Despite this,
comparatively little is known of the biochemical mechanisms that regulate the expression of integrin genes in
cells. Here we demonstrate that the Ras-activated Raf–MEK–extracellular signal-regulated kinase (ERK)
signaling pathway can specifically control the expression of individual integrin subunits in a variety of human
and mouse cell lines. Pharmacological inhibition of MEK1 in a number of human melanoma and pancreatic
carcinoma cell lines led to reduced cell surface expression of a6- and b3-integrin. Consistent with this,
conditional activation of the Raf-MEK-ERK pathway in NIH 3T3 cells led to a 5 to 20-fold induction of cell
surface a6- and b3-integrin expression. Induced b3-integrin was expressed on the cell surface as a heterodimer
with av-integrin; however, the overall level of av-integrin expression was not altered by Ras or Raf. Raf-
induced b3-integrin was observed in primary and established mouse fibroblast lines and in mouse and human
endothelial cells. Consistent with previous reports of the ability of the Raf-MEK-ERK signaling pathway to
induce b3-integrin gene transcription in human K-562 erythroleukemia cells, Raf activation in NIH 3T3 cells
led to elevated b3-integrin mRNA. However, unlike immediate-early Raf targets such as heparin binding
epidermal growth factor and Mdm2, b3-integrin mRNA was induced by Raf in a manner that was cyclohex-
imide sensitive. Surprisingly, activation of the Raf-MEK-ERK signaling pathway by growth factors and
mitogens had little or no effect on b3-integrin expression, suggesting that the expression of this gene requires
sustained activation of this signaling pathway. In addition, despite the robust induction of cell surface
avb3-integrin expression by Raf in NIH 3T3 cells, such cells display decreased spreading and adhesion, with
a loss of focal adhesions and actin stress fibers. These data suggest that oncogene-induced alterations in
integrin gene expression may participate in the changes in cell adhesion and migration that accompany the
process of oncogenic transformation.
Adhesion of cells to extracellular matrix (ECM) is mediated
by a family of transmembrane proteins known as integrins that
are expressed on the cell surface as a/b-heterodimers (21, 30,
40). Different combinations of a and b subunits give rise to a
multiplicity of ECM receptors, the expression of which shows
considerable cell type specificity (40). Moreover, the intracel-
lular regions of integrin subunits are believed to mediate the
assembly of components of the focal adhesion complex, which
in turn participate in marshalling the actin cytoskeleton (14, 21,
72). Regulation of integrin function is believed to be essential
in promoting stable cell adhesion as well as being required for
cell migration.
In addition to their role in cell adhesion and migration,
engagement and clustering of integrins elicits a series of signal
transduction events that participate in the control of cell cycle
progression and apoptosis in a process known as “outside-in”
signaling. For example, integrin engagement can elicit activa-
tion of members of the Src and FAK family of protein tyrosine
kinases (26, 49). These initial signaling events promote the
activation of Ras and Rho family GTPases that in turn influ-
ence the activation of a number of intracellular signaling path-
ways (16, 47). A second mode of integrin regulation known as
“inside-out” signaling has also been described. For example,
the Ras-activated Raf–MEK–extracellular signal-regulated ki-
nase (ERK) signaling pathway can influence the activation
state of the aIIbb3 (also known as gpIIb/IIIa) integrin as
measured by the binding of a monoclonal antibody that rec-
ognizes the activated form of this integrin. Interestingly, the
mechanism of alteration of the aIIbb3 integrin affinity state is
independent of de novo RNA and protein synthesis and may
be due to the direct modification of preexisting integrin sub-
units on the surface of the cell (39).
In addition to their role in normal cell physiology, there is an
extensive body of literature indicating that alterations in the
expression of specific integrin subunits on the surface of cancer
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cells contributes to the invasive and metastatic properties of
the cells (43, 67, 79). For example, reduced expression of
a5b1-integrin in K-562, CHO, and HT-29 cells and of a2b1 in
breast cancer cells correlates with increased tumorigenicity.
Moreover, in certain circumstances, elevated expression of a6-,
a3- or b3-integrins appears to be closely associated with on-
cogenic transformation and tumor progression. Indeed, there
is strong evidence that the expression of avb3-integrin is tightly
correlated with the acquisition of invasive and/or metastatic
behavior by melanoma and glioblastoma cells (1, 29, 32, 59, 61,
71, 78). Moreover, ectopic expression of avb3-integrin in a
benign human melanoma cell line can promote invasion and
metastasis when tested in a mouse xenograft assay (50).
In addition to a direct role in promoting tumor cell invasion
and migration, avb3-integrin is implicated in the angiogenesis
and neovascularization of tumors by normal endothelial cells.
The induced expression of this integrin heterodimer on the
surface of sprouting endothelial cells is believed to be essential
for endothelial cell migration, proliferation, and tubulogenesis
(10, 41, 79, 80). Indeed, direct binding of the MMP-2 matrix
metalloprotease to avb3-integrins may be important in pro-
moting localized ECM degradation and cell invasion (12). For
these reasons, a number of avb3-integrin antagonists are being
clinically tested for their efficacy in treating cancer (11, 36, 57).
Despite the extensive literature on the role of integrins in
cancer, little is known about the intracellular signaling path-
ways that regulate the expression of integrin genes in cancer
cells (9, 83, 85). Here we demonstrate that pharmacological
inhibition of MEK1 activity led to decreased expression of a6-
and b3-integrins in a number of human melanoma and pan-
creatic carcinoma cell lines, consistent with a role for the Raf-
MEK-ERK pathway in regulating integrin gene expression in
certain human tumors. Moreover, selective activation of the
Raf-MEK-ERK pathway in NIH 3T3 cells led to increased
expression of a number of integrins, of which b3- and a6-
integrin were most prominent. Raf-induced b3-integrin expres-
sion was observed in a variety of mouse fibroblasts and in
mouse and human endothelial cells. In NIH 3T3 cells, induced
expression of b3-integrin was preceded by increased b3-inte-
grin mRNA, consistent with the previously described ability of
the Raf-MEK-ERK signaling pathway to transactivate the b3-
integrin gene (44, 81, 83, 85). Surprisingly, b3-integrin was
induced in response to sustained activation of the Raf-MEK-
ERK signaling pathway and not in response to the transient
activation of this pathway elicited by growth factors and mito-
gens. However, despite the induced expression of avb3-inte-
grins on the surface of NIH 3T3 cells, Raf-transformed cells
displayed profound alterations in intracellular architecture and
cell morphology, leading to decreased cell adhesion and in-
creased cell motility. These data indicate that signaling path-
ways downstream of Ras can influence the expression of inte-
grin genes associated with invasion and metastasis of human
tumor cells.
MATERIALS AND METHODS
Retrovirus expression vectors. Vectors for the expression of DRaf:ER* and
DMEK1:ER* proteins were generated by fusing DNA sequences encoding acti-
vated forms of A-Raf, Raf-1, B-Raf, or MEK1 to a modified form of the
hormone binding domain of the mouse estrogen receptor (ERTM) that responds
to 4-hydroxytamoxifen (4-HT) and ICI compounds but not to 17-b-estradiol or
phenol red as described previously (51). DNA sequences encoding DRaf:ER*
and DMEK1:ER* were inserted into the replication-defective retrovirus vector
pBabepuro3 (pBP3) for expression in mammalian cells (60). Retrovirus con-
structs expressing EGFPDRaf-1:ER, c-Myc:ERTM, and Akt:ER* have been de-
scribed previously (48, 51, 88). Retrovirus vectors (pZAS4) encoding v-Myc or
v-Ha-Ras and resistance to mycophenolic acid were provided by J. Kaplan (45).
Additional details of retrovirus expression vectors are available on request.
Cell culture, virus production, and virus infection. Cells were cultured at 37°C
in a humidified atmosphere containing 6% (vol/vol) CO2, in phenol red-free
Dulbecco’s modified Eagle’s medium supplemented with 10% (vol/vol) fetal calf
serum (FCS), penicillin, streptomycin and gentamicin. 4-HT (Sigma) was stored
at 220°C as a 1 mM stock in ethanol and diluted directly into the cell culture
medium. Ecotropic or amphotropic retrovirus stocks were obtained by transient
transfection of retroviral vector DNAs into either BOSC 23, Phoenix-E, or
Phoenix-A packaging cells and used to infect target cells as described previously
(63, 88). NIH 3T3 cells expressing the TrkA/nerve growth factor (NGF) receptor
were provided by Kevin Pumiglia and Stu Decker and cultured as described
previously (65).
Cell staining and flow cytometry. Cells were cultured as described above and
stimulated as described in the text. They were harvested by trypsinization and
washed with Flow medium (Ca21- and Mg21-free phosphate-buffered saline
containing 1% [wt/vol] bovine serum albumin and 1 mM sodium azide) prior to
staining. Phycoerythrin (PE) or biotin-coupled anti-integrin antisera used for
murine cell staining were purchased from Pharmingen: anti-b1-biotin (CD29,
Ha2/5), anti-b3-PE (CD61, 2C9.G2), anti-b4 (CD104, 346-11A), anti-av-biotin
(CD51, H9.2B8), anti-a1 (CD49a, Ha31/8), anti-a2 (CD49b, HMa2), anti-a4-PE
(CD49d, R1-2), anti-a5-PE (CD49e, 5H10-27), and anti-a6-PE (CD49f, GoH3).
Avidin-PE, avidin-fluorescein isothiocyanate (FITC), goat F(ab9)2 fragments,
and anti-rat PE secondary reagents were obtained from Caltag or Vector Lab-
oratories. Anti-hamster immunoglobulin G-biotin (secondary reagent for anti-
a1- and anti-a2 integrin in conjunction with avidin-PE) was obtained from
Pharmingen. Human b3-integrin was detected using a PE-coupled mouse mono-
clonal antibody (MAb) (VI-PL2) with a similarly coupled MAb (MOPC-21) as
an isotype control (Pharmingen). Human a6-integrin was detected using an
FITC-coupled rat MAb (GoH3) with a rat immunoglobulin G2a (R35-95) as an
isotype control (Pharmingen). Cells were stained in 100 ml of Flow buffer,
analyzed using a FACScalibur flow cytometer and quantitated using CellQuest
software (Becton Dickinson).
Biotinylation and Western blotting. Cells were biotinylated using membrane-
impermeant NHS-LC-biotin (Pierce Chemicals) dissolved at 0.5 mg/ml in Tris-
buffered saline (TBS) and incubated at room temperature for 30 min. The cells
were washed with phosphate-buffered saline and harvested into Gold lysis buffer
(GLB) containing 1% (vol/vol) Triton X-100 (33, 70). b3-Integrin was immuno-
precipitated using an antiserum raised against the intracellular region of the
protein, kindly provided by Mark Ginsberg. Immune complexes were collected
using protein A-agarose and subjected to sodium dodecyl sulfate-polyacrylamide
gel electrophoresis and Western blots were prepared. The Western blots were
probed with streptavidin coupled to horseradish peroxidase (HRP) (Amersham)
and visualized using the enhanced chemiluminescence technique (Amersham).
The same antiserum was used to detect b3-integrin in GLB extracts of whole
cells by standard Western blotting techniques. Phospho-specific anti-ERK1 and
anti-ERK2 antisera and antisera against ERK1 and ERK2 were from New
England Biolabs and Santa Cruz Biotechnology, respectively, and were used as
previously described (4).
Fluorescence microscopy. NIH 3T3 cells in the absence or presence of acti-
vated Raf were fixed in 4% (wt/vol) paraformaldehyde, permeabilized with 0.1%
(vol/vol) Triton X-100, and then stained with phalloidin-FITC (Molecular
Probes), as specified by the manufacturer, to visualize polymerized actin. To
detect focal adhesions, fixed and permeabilized cells were costained with an
anti-vinculin MAb (VIN-11-5 [Sigma], 1:100 dilution) and visualized using a
Texas red-coupled anti-mouse antiserum. Dual fluorescence of the FITC and
Texas red fluorophores was visualized using a Nikon microscope equipped with
a 1003 oil immersion lens and the appropriate fluorescence filter sets. Cells were
photographed using a Nikon camera and 400ASA Kodak color film.
Quantitation of cellular mRNAs. The expression of cellular mRNAs was
quantitated using a simultaneous RNase protection assay (RPA) as described
previously (53, 55). RPA probes for mouse heparin binding epidermal growth
factor (HB-EGF) and glyceraldehyde-3-phosphate dehydrogenase (GAPDH)
mRNAs have been described previously (53, 55). The RPA probe for mouse
b3-integrin was prepared by in vitro transcription of a 600-bp coding-sequence
fragment, which was linearized with EcoRI and transcribed using T7 RNA
polymerase.
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RESULTS
Regulation of integrin subunit expression by the Raf-MEK-
ERK signaling pathway in human cancer cells. Expression of
a6- or b3-integrin in certain human cancer cells is associated
with progression to a more invasive and/or metastatic state
(79). To determine if the Ras-regulated Raf-MEK-ERK path-
way may play a role in the regulation of these integrin subunits,
we assessed the expression of b3- and a6-integrin in human
CFPAC pancreatic cancer cells and WM793 melanoma cells.
CFPAC cells express activated K-Ras, but the activation status
of the Raf-MEK-ERK pathway in WM793 cells is unknown
(31). The cells were treated with either UO126, a pharmaco-
logical inhibitor of MEK1, SB203,580, a pharmacological in-
hibitor of p38 mitogen-activated protein (MAP) kinase, or
dimethyl sulfoxide (DMSO) as a solvent control, and the ex-
pression of cell surface b3- and a6-integrins was assessed by
cell staining and flow cytometry (Fig. 1). In both CFPAC (Fig.
1A to D) and WM793 (Fig. 1E to H) cells, inhibition of MEK1
by UO126 completely abolished the cell surface expression of
both b3-integrin (Fig. 1A and C) and a6-integrin (Fig. 1E and
G). SB203,580 led to a modest decrease in b3-integrin expres-
sion in both CFPAC and WM793 cells, whereas it had little or
no effect on the expression of a6-integrin in these cells. Similar
experiments conducted with a panel of pancreatic cancer and
melanoma cell lines revealed that inhibition of MEK1 by
UO126 led to decreased b3-integrin expression in four of
seven pancreatic cancer cell lines (CFPAC, BxPC3, AsPC1,
and Capan-2) and four of four melanoma cell lines (WM793,
WM9, WM164, and WM1205) tested. These data indicate that
cell surface a6- and b3-integrin expression is promoted by the
Raf-MEK-ERK signaling pathway in certain human cancer
cell lines.
Cell surface expression of integrins following Raf activation
in NIH 3T3 cells. We have previously described the utility of
conditionally active forms of Raf protein kinases (Raf:ER) in
exploring the role of the Raf-MEK-ERK pathway in a variety
of physiological processes (70). Addition of 4-HT to NIH 3T3
cells expressing DRaf-1:ER elicits immediate activation of
MEK1, ERK1, and ERK2, leading to rapid changes in gene
expression (54, 55). At 16 to 24 h after DRaf-1:ER activation,
NIH 3T3 cells show dramatic alterations in cell morphology
(70) (see Fig. 8).
To determine if activation of the Raf-MEK-ERK pathway
can lead to alterations in integrin gene expression, NIH 3T3
cells expressing DB-Raf:ER* (88) were either untreated or
treated with 4-HT for 24 h, at which time cell surface integrin
expression was assessed by flow cytometry (FACScan) of cells
stained with a panel of anti-integrin MAbs as described in
Materials and Methods. As controls, the cells were stained with
the appropriate antibody isotypes in the absence or presence of
activated Raf (data not shown). Raf activation had little or no
effect on the expression of a1-, a2-, a4-, av-, or b4-integrin
subunits (Fig. 2). However, Raf activation led to increased
expression of a5-, a6-, b1-, and, most strikingly, b3-integrin. A
10- to 30-fold induction of b3-integrin expression was observed
in multiple iterations of this experiment using both clonal and
pooled populations of NIH 3T3 cells expressing DB-Raf:ER*.
The ability of Raf to induce b3-integrin expression was unaf-
fected by the absence or presence of FCS. Furthermore, in-
duction of b3-integrin was observed at both low and high levels
of Raf activation, which promote or inhibit NIH 3T3 cell cycle
progression, respectively (88). No alterations in integrin sub-
unit expression were detected in parental NIH 3T3 cells or in
cells expressing a kinase-inactive DRaf-1:ER fusion protein in
the absence or presence of 4-HT (data not shown). Further-
more, no alterations in b3-integrin expression were observed
following addition of 4-HT to NIH 3T3 cells expressing con-
ditionally active Akt (Akt:ER*) or c-Myc (c-Myc:ERTM) (data
not shown) (24, 48, 51, 58). Finally, as observed in the human
cancer cell lines in Fig. 1, induction of b3-integrin by DB-Raf:
ER* was inhibited by the selective MEK1 inhibitors PD098059
and UO126 but not by LY294002, an inhibitor of phosphati-
dylinositol 39-kinase (23, 25). Taken together, these data sug-
gest that the Raf-MEK-ERK pathway can influence the ex-
pression of a specific subset of integrin subunits on the surface
of NIH 3T3 cells. Moreover, in NIH 3T3 cells, as in human
cancer cells, Raf-induced b3-integrin expression requires the
downstream activation of MEK.
To confirm these data, we assessed the ability of condition-
ally active forms of A-Raf, Raf-1, and MEK1 to induce the
expression of b3-integrin (4, 8, 64). Pooled populations of NIH
3T3 cells expressing DA-Raf:ER*, DRaf-1:ER*, DB-Raf:ER*,
or DMEK1:ER* were derived by retrovirus infection as de-
scribed in Materials and Methods. As expected, addition of
4-HT to cells expressing DA-Raf:ER*, DRaf-1:ER*, DB-Raf:
ER*, or DMEK1:ER* led to induced b3-integrin expression
(Fig. 3). In general, the kinetics of b3-integrin induction were
more rapid in response to conditional activation of B-Raf and
Raf-1 activity (data not shown), consistent with the fact that
these forms of Raf are more potent activators of the ERK
MAP kinase pathway than is A-Raf or MEK1 (4, 8, 64, 88).
Finally, infection of NIH 3T3 cells with a retrovirus encoding
oncogenic v-Ha-Ras, but not a similar virus encoding v-Myc,
led to induced b3-integrin expression (Fig. 4A). To define which
pathways downstream of Ras were required for b3-integrin
induction, we utilized NIH 3T3 cells expressing various effector
domain mutants of Ras (82, 84). A form of activated human
H-Ras that is capable of activating the Raf-MEK-ERK path-
way (T35S) induced b3-integrin expression in NIH 3T3 cells.
However, forms of H-Ras that activate phosphatidylinositol
39-kinase (Y40C) or Ral.GDS (E37G), but fail to activate the
Raf-MEK-ERK pathway also failed to induce b3-integrin ex-
pression in NIH 3T3 cells (data not shown). Taken together,
these data are consistent with a model in which the Ras-
activated Raf-MEK-ERK pathway can regulate cell surface
b3-integrin expression in NIH 3T3 cells.
To test whether the ability of Raf to induce b3-integrin was
a property solely of NIH 3T3 cells, we derived populations of
primary mouse embryo fibroblasts, BALB/c cells, and Swiss
3T3 cells expressing EGFPDRaf-1:ER, a green fluorescent
protein-tagged form of conditional Raf-1 (88, 90). Activation
of EGFPDRaf-1:ER in all of these cells led to induced b3-
integrin expression (data not shown). Moreover, since b3-in-
tegrin plays an important role in the invasion and migration of
endothelial cells, we expressed EGFPDRaf-1:ER in the mouse
endothelioid cell lines MS-1 and SVEC. Although the basal
levels of b3-integrin expression were considerably higher in
these cells than in mouse fibroblasts, Raf activation led to
elevated cell surface b3-integrin expression (data not shown).
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FIG. 1. Expression of b3- and a6-integrins in human cancer cell lines. CFPAC pancreatic cancer cells (A to D) or WM793 melanoma cells (E
to H) were treated with either UO126, SB203,580, or DMSO as a solvent control for 48 h as indicated and then stained for the cell surface
expression of b3- or a6-integrins by flow cytometry as described in Materials and Methods.
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FIG. 2. Expression of integrin subunits following Raf activation in NIH 3T3 cells. NIH 3T3 cells expressing DB-Raf:ER* were either untreated
(dotted line) or treated with 100 nM 4-HT for 24 h (solid line) at which time the cells were harvested and either left unstained or stained for the
cell surface expression of particular a- and b-integrin subunits as indicated. The expression of integrin subunits was detected by flow cytometry
as described in Materials and Methods.
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Finally, using the catalytic subunit of telomerase (hTERT), we
have derived telomerase immortalized human microvascular
endothelial (TIME) cells that retain the endothelial character-
istics of the primary cells from which they were derived (E.
Venetsanakos and M. McMahon, unpublished data). By sub-
sequent retrovirus infection, we derived TIME cells express-
ing EGFPDRaf-1:ER. As with the mouse endothelioid cell
lines, TIME cells express a high basal level of b3-integrin on
the surface of the cell; however, subsequent activation of
EGFPDRaf-1:ER led to increased expression of b3-integrin
(Fig. 4B). These data suggest that the Raf-MEK-ERK pathway
has the capacity to regulate the expression of b3-integrin in a
number of human and mouse cell types.
Induction of cell surface av b3-integrin heterodimers by Raf
and MEK. To confirm the results obtained by flow cytometry,
proteins on the surface of NIH 3T3 cells were biotinylated at
different times after the activation of DRaf:ER* or DMEK-1:
ER*. Cell extracts were prepared, and b3-integrin (and asso-
ciated proteins) was immunoprecipitated under nonreducing
conditions using an antiserum against the carboxy terminus of
the protein (gift of Mark Ginsberg, Scripps Institute). Western
blots were prepared, and biotinylated proteins in the immuno-
precipitates were detected using streptavidin coupled to horse-
radish peroxidase (Fig. 5). As expected from the flow cytom-
etry experiments, activation of DRaf:ER* or DMEK1:ER*
proteins led to induced expression of the 97-kDa b3-integrin
subunit that was detected between 8 and 24 h after 4-HT
addition. In each cell line a protein of approximately 125 kDa
was observed to coimmunoprecipitate with the induced b3-
integrin. b3-Integrin forms heterodimers with only two differ-
ent a-integrin subunits: the 125-kDa av subunit and the 114-
kDa gpIIb subunit. Since gpIIb expression is restricted to
megakaryocytes and platelets and is not expressed in fibro-
blasts, it seemed highly likely that the coprecipitating protein
corresponded to av-integrin. This was confirmed by reciprocal
immunoprecipitations of these cell lysates with antisera against
av-integrin, which coprecipitated Raf-induced b3-integrin
(data not shown). Hence, prior to Raf activation, NIH 3T3
cells express av-integrin that is readily detected by flow cytom-
etry, presumably as a heterodimer with a variety of other b-in-
tegrin subunits (40, 73) (Fig. 2). Experiments presented here
suggest that following Raf activation all of the cells express
b3-integrin as a heterodimer with av-integrin without any
change in the overall level of av-integrin expression (Fig. 2).
Consequently, these data suggest that Raf-induced b3-integrin
expression most likely leads to a reassortment of the pattern of
integrin heterodimers found on the surface of the cell.
FIG. 3. Induction of b3-integrin by Raf and MEK1. NIH 3T3 cells expressing DA-Raf:ER*, DRaf-1:ER*, DB-Raf:ER*, or DMEK1:ER* were
either left untreated or treated with 100 nM 4-HT for 48 h, at which time the cells were harvested and stained for the cell surface expression of
b3-integrin as described in Materials and Methods. The expression of b3-integrin subunits was detected by flow cytometry.
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Raf-induced b3-integrin mRNA. To determine the mecha-
nism by which Raf induced b3-integrin expression, RNA sam-
ples were isolated from NIH 3T3 cells at different times after
the activation of DB-Raf:ER*. This experiment was conducted
in the absence or presence of FCS or cycloheximide, as indi-
cated in Fig. 6. These conditions allowed us to determine
whether changes in mRNA expression are immediate-early, as
defined by cycloheximide sensitivity, or if they require the
presence of serum factors. The expression of b3-integrin, HB-
EGF, and GAPDH mRNAs was assessed using an RPA (Fig.
6A to C, respectively). HB-EGF is a previously characterized,
AP-1/Ets regulated, immediate-early Raf-responsive gene, and
GAPDH mRNA is unaffected by Raf activation (54, 55).
Activation of DB-Raf:ER* led to induced expression of both
b3-integrin and HB-EGF mRNAs. However, the induction of
b3-integrin mRNA lagged behind that of HB-EGF, which was
maximally induced after 3 h of Raf activity. As demonstrated
previously, the induction of HB-EGF mRNA by Raf was re-
sistant to cycloheximide and was unaffected by the absence of
FCS (Fig. 6B). Indeed, HB-EGF mRNA was superinduced by
Raf in the presence of cycloheximide (55). By contrast, al-
though the induction of b3-integrin mRNA was unaffected by
the absence of FCS, it was abrogated by pretreatment of cells
with cycloheximide (Fig. 6A). The level of GAPDH mRNA
was unaffected by DB-Raf:ER* activation. These data indicate
that the induced expression of cell surface b3-integrin is prob-
ably mediated by elevated expression of its cognate mRNA.
Moreover, like cyclin D1, b3-integrin is a delayed-early target
of the Raf-MEK-ERK signaling pathway in NIH 3T3 cells (4).
These data are consistent with previous observations that
phorbol esters can induce the de novo transcription of the
b3-integrin gene in K-562 cells through the Raf-MEK-ERK
pathway (44, 81, 83, 85).
Induction of b3-integrin by sustained activation of the ERK
MAP kinase pathway. A large number of Ras- and Raf-respon-
sive genes such as those encoding Mdm2, HB-EGF, transform-
ing growth factor b1, c-Myc, Fra-1, JunB, cyclin D1, and
p21Cip1 have been identified by many groups (4, 6, 19, 46, 55,
66, 76, 88). Invariably such genes are also induced by mitogens
such as FCS, lysophosphatidic acid, phorbol esters, or specific
polypeptide growth factors that activate the Raf-MEK-ERK
signaling pathway such as platelet-derived growth factor
(PDGF) or EGF. On the assumption that b3-integrin might
also be mitogen induced, serum-deprived NIH 3T3 cells ex-
pressing EGFPDRaf-1:ER were treated for 12 or 24 h with
concentrations of EGF, PDGF, FCS, or phorbol esters suffi-
cient to activate the Raf-MEK-ERK pathway leading to cell
cycle progression. As a control, cells were treated with 4-HT to
activate Raf. Cell extracts were prepared, and b3-integrin ex-
pression was assessed by Western blotting (Fig. 7A). As ex-
pected, activation of Raf led to robust induction of b3-integrin
expression, but, to our surprise, b3-integrin expression was not
induced by the various mitogens used in this experiment. It
appeared that the induction of b3-integrin in this experiment
correlated with the sustained activation of ERK1 and ERK2
that is observed in Ras- and Raf-transformed cells (Fig. 7B).
To confirm this observation, this experiment was repeated us-
ing parental NIH 3T3 cells as well as other clonal and pooled
populations of DRaf:ER-expressing cells. Under no circum-
stances did we observe b3-integrin induction by growth factor
or mitogen treatment of NIH 3T3 cells. In addition, this ex-
periment was repeated to include a larger number of earlier
and later time points spanning a time course from 6 to 72 h
following mitogen addition to ensure that we had not simply
failed to detect a transient induction of b3-integrin by the
choice of time points in the initial experiments. In these latter
experiments, b3-integrin expression was detected by cell stain-
ing with anti-b3-integrin antisera and flow cytometry, a more
sensitive measure of expression. Again, b3-integrin was in-
duced by Raf activation but was not observed at any time in
response to the mitogens or growth factors listed above (data
FIG. 4. Induction of b3-integrin by Ras. (A) NIH 3T3 cells were
infected with retroviruses encoding either v-Myc or v-Ha-Ras, and
virus-infected cells were selected over 14 days in mycophenolic acid as
described in Materials and Methods. Parental (dotted line), v-Myc-
expressing (solid line), and v-Ha-Ras-expressing (filled curve), cells
were stained for the cell surface expression of b3-integrin. (B) Human
microvascular endothelial cells immortalized by the expression of the
catalytic subunit of telomerase and expressing EGFPDRaf-1:ER were
derived by the use of the appropriate amphotropic retroviruses. Cells
were either left untreated (thin line) or treated with 1 mM 4-HT (thick
line), at which time they were stained either with an isotype control
(dotted line) or with an antiserum that recognizes human b3-integrin.
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not shown). The failure of these agents to induce b3-integrin
expression was not a reflection of their inability to induce cell
cycle progression since we and others have demonstrated that
all of these agents are potent inducers of DNA synthesis in
quiescent NIH 3T3 cells (64, 69). In addition, induction of
b3-integrin by sustained activation of the Raf-MEK-ERK
pathway was not a property of all delayed-early genes since
cyclin D1 was induced efficiently in NIH 3T3 cells by all of the
agents tested in this experiment (data not shown).
A major difference between the activation of the ERK MAP
kinases by Raf and that mediated by mitogens or polypeptide
growth factors is that Raf elicits sustained ERK activation
FIG. 5. Elevated avb3-integrin expression on the surface of Raf-transformed cells. NIH 3T3 cells expressing DA-Raf:ER* (A), DB-Raf:ER*
(B), DRaf-1:ER* (C), or DMEK1:ER* (D) were either left untreated (0 h) or treated with 100nM 4-HT for 4, 8, 24, or 48 h as indicated. Cells
were then subjected to biotinylation using the membrane-impermeant reagent NHS-LC-biotin. Cell extracts were prepared, and b3-integrin and
its associated proteins were immunoprecipitated using a polyclonal anti-b3-integrin antiserum. Immunoprecipitates were resolved by sodium
dodecyl sulfate-polyacrylamide gel electrophoresis and Western blots were prepared. Biotinylated proteins in the immunoprecipitates were
detected by probing the Western blots with streptavidin-horseradish peroxidase.
FIG. 6. Delayed-early induction of b3-integrin mRNA by Raf. NIH 3T3 cells expressing DB-Raf:ER* in the absence or presence of FCS were
either left untreated (2CHX) or treated with 10 mg of cycloheximide per ml (1CHX) for 1 h. At this time, the cells were either left untreated
(0 h) or treated with 1 mM 4-HT for 3, 5, or 7 h as indicated. At this time, total cellular RNA was prepared and probed for the expression of
b3-integrin (A), HB-EGF (B), and GAPDH (C) mRNAs using a simultaneous RPA as described in Materials and Methods.
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whereas the other agents activate ERKs with transient kinetics.
Others have reported that NGF treatment of NIH 3T3 cells
expressing the NGF receptor leads to sustained ERK activa-
tion and induction of p21Cip1-mediated cell cycle arrest in a
manner identical to that elicited by Raf (65, 88). When we
treated these cells with NGF, we observed induced expression
of b3-integrin, concomitant with p21Cip1 induction, consistent
with the hypothesis that b3-integrin expression requires sus-
tained ERK MAP kinase activation (Fig. 7D). Furthermore,
these data suggest that the induction of b3-integrin is not
specific to Ras or Raf per se but requires sustained activation
of the ERK MAP kinase pathway that may be elicited by a
number of means.
Effects of Raf activation on intracellular architecture and
cell morphology. The avb3-integrin complex is an important
receptor for vitronectin in mouse fibroblasts but is also capable
of promoting adhesion to a variety of other ECM proteins (38).
Consequently, the induced expression of avb3-integrin on the
surface of NIH 3T3 cells might be expected to promote cell
adhesion and spreading as well as to promote the formation of
focal adhesions and assembly of actin stress fibers. To address
this, NIH 3T3 cells expressing DB-Raf:ER* were plated on
vitronectin-coated coverslips in the presence of FCS and either
left untreated or treated with 4-HT for 24 h (Fig. 8C and D).
These cells were stained to detect polymerized and bundled
actin (green) or vinculin (red) and to detect assembled focal
adhesions at the tips of actin stress fibers (yellow) as described
in Materials and Methods. For comparison, phase-contrast
photomicrographs (at a lower magnification) of similarly
treated cells are also presented (Fig. 8A and B).
Prior to Raf activation, NIH 3T3 cells display a flat, non-
refractile cell morphology and display contact inhibition
(Fig. 8A). Such cells have abundant actin stress fibers and
focal adhesions and display little detectable cortical actin
(Fig. 8C). Furthermore, these cells require trypsinization to
remove them from the dish and, when observed by time-
lapse cinemicroscopy, are relatively nonmotile. By contrast,
cells expressing activated DRaf-1:ER display a highly
rounded, refractile morphology with numerous cell exten-
sions and pile up on one another as a consequence of the
loss of contact inhibition (Fig. 8B). Moreover, these cells
display an almost complete loss of focal adhesions, have
significantly reduced numbers of actin stress fibers, and dis-
play elevated levels of cortical actin, which is often associ-
ated with membrane ruffling (Fig. 8D). Importantly, the
overall expression of vinculin, paxillin, and FAK is un-
FIG. 7. Induction of b3-integrin by sustained ERK MAP kinase
activation. (A to C) NIH 3T3 cells expressing EGFPDRaf-1:ER were
cultured in serum-free medium for 36 h prior to the addition of 10 ng
of EGF per ml, 20% (vol/vol) FCS, 1 mM 4-HT, 0.1% (vol/vol) ethanol
(EtOH), 50 ng of phorbol esters per ml (PMA), or 10 ng of PDGF per
ml for 12 or 24 h. Cell extracts were prepared and probed for the
expression of b3-integrin (A), the activation of the ERK MAP kinases
(B), and the overall expression of the ERK MAP kinases as a loading
control (C) using the appropriate antisera as described in Materials
and Methods. (D) NIH 3T3 cells expressing the NGF receptor (65)
were either left untreated or treated with 10 ng of NGF per ml for 24
or 48 h, at which time the expression of b3-integrin and p21Cip1 was
assessed by Western blotting with the appropriate antisera.
3200 WOODS ET AL. MOL. CELL. BIOL.
 o
n
 February 4, 2015 by Thom
as Jefferson Univ
http://m
cb.asm
.org/
D
ow
nloaded from
 
changed in Raf-transformed cells; therefore the loss of de-
tectable focal adhesions is not due to reduced expression of
these crucial components. In addition, Raf-transformed
cells are readily detached from the dish without the use of
trypsin. Finally, when observed by time-lapse cinemicros-
copy, Raf-transformed cells display a high degree of cell
motility (A. Bhat, unpublished observations). These data
indicate that, although Raf promotes the expression of cell
surface avb3-integrin, the effects of Raf on intracellular
architecture, cell morphology, and adhesion run counter to
the simple expectation that cell-ECM attachment might be
increased in these cells.
FIG. 8. Raf-transformed fibroblasts display alterations in intracellular architecture and cell morphology. (A and B) NIH 3T3 cells expressing
DB-Raf:ER* were either left untreated (A) or treated with 1 mM 4-HT for 24 h (B), at which time they were photographed using a Polaroid
charge-coupled device camera. Total magnification, ca. 380. (C and D) NIH 3T3 cells expressing DB-Raf:ER* were plated on vitronectin-coated glass
microscope slides and either left untreated (C) or treated with 1 mM 4-HT for 24 h (D). At this time, the cells were fixed and costained with
phalloidin-FITC to visualize polymerized actin (green) and antivinculin antisera to visualize focal adhesions (red). Areas of colocalization are false
colored in yellow. Total magnification, ca. 3400.
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DISCUSSION
Although alterations in the expression and activity of inte-
grins have been reported to play an important role in the
acquisition of migratory, invasive, or metastatic properties by
human tumor cells, the signal transduction pathways that elicit
these changes remain poorly characterized (43, 67, 79). Here
we demonstrate that the Raf-MEK-ERK signaling pathway
can promote the expression of a6- and b3-integrin. These
integrin subunits have previously been associated with in-
creased invasion and metastasis of a number of human tumor
cells. Although the mechanisms of a6-integrin induction by the
Raf-MEK-ERK pathway remain to be elucidated, induced cell
surface b3-integrin expression is accompanied by elevated b3-
integrin mRNA levels. The Raf-MEK-ERK pathway promoted
the expression of b3-integrin in a number of nontransformed
fibroblastic and endothelial cells as well as in a number of
human cancer cell lines. However, b3-integrin induction is not
a universal marker for the sustained activation of the ERK
MAP kinase pathway in mammalian cells. Indeed, Raf activa-
tion in RIE-1 rat colonic epithelial cells, DKO-4 human colon
cancer-derived cells, and IMR-90 human fibroblasts had no
effects on b3-integrin expression (references 5, 66, 74, and 90
and data not shown). These data are consistent with the fact
that b3-integrin is associated with the invasion and metastasis
of specific types of human cancers (79). However, it is possible
that Raf activation may lead to alterations in the expression or
activity of other integrin subunits in different cell types.
There is at least one other situation where the expression of
b3-integrin is under the control of the Raf-MEK-ERK path-
way. Phorbol ester treatment or expression of activated MEK1
in human K-562 erthyroleukemia cells leads to coordinate in-
duction of both b3-integrin and its heterodimerization partner
in megakaryocytes and platelets, aIIb-integrin (44, 83). Under
these circumstances, the Raf-MEK-ERK pathway promotes
the transcriptional activation of the b3-integrin gene. Although
the transcription factors required for b3-integrin induction are
unknown, the gene promoter has potential binding sites for
MZF-1, Sp1, GATA, Myb, Ets, and E2F transcription factors
(81). Although there is precedent for ERK-mediated regula-
tion of Ets and Sp1 transcription factors, further analysis of the
promoter is required to confirm a role for these transcription
factors in the control of b3-integrin expression in both NIH
3T3 and K-562 cells (52, 54, 56, 84, 89). Moreover, it is not
clear if b3-integrin induction by the Raf-MEK-ERK pathway
in NIH 3T3 cells relies on the same biochemical mechanisms
observed in K-562 cells. Hence, a comparative analysis of these
two cell types is currently under way using NIH 3T3 and K-562
cells expressing conditionally active forms of Raf and MEK1.
An unanticipated observation in this study was the apparent
inability of mitogens and growth factors to induce b3-integrin
expression in NIH 3T3 cells. To our knowledge, the b3-inte-
grin gene is the first gene induced as a consequence of the
sustained activation of the ERK MAP kinase pathway elicited
by activated Ras, Raf, and MEK but not by growth factors and
mitogens that elicit transient ERK MAP kinase activation.
This raises the possibility that the b3-integrin gene may be a
member of a group of genes that display similar properties.
The advent of cDNA microarrays and high-throughput gene
expression analysis will allow us to search for such genes in a
systematic fashion (22, 42). Having identified the transcription
factors that mediate Raf induction of b3-integrin, it will be
interesting to determine why sustained, but not transient, Raf
activation elicits b3-integrin expression and if there are addi-
tional signals specific to transformed cells that are required for
b3-integrin expression (2, 68, 75).
It is interesting that, in principle, the induced expression of
even a single integrin subunit could have significant effects on
the global pattern of integrin heterodimers expressed on the
surface of the cell. In this case the induction of b3-integrin was
not accompanied by a concomitant increase in the expression
of its heterodimerization partner av-integrin. Since b3-integrin
must appropriate a certain amount of av-integrin for its cell
surface expression, it seems reasonable to surmise that there
must be a reassortment of the dimerization of b-integrin sub-
units on the surface of the cell or down-regulation of the
expression of b-integrin subunits that form heterodimers with
av such as b5-, b6- and b8-integrins. Unfortunately, cell-stain-
ing reagents for flow cytometry were not available to assess the
expression of these integrins in mouse cells. Such observations
are compounded by the fact that Raf also induced the expres-
sion of other integrin subunits such as a6. In addition to effects
on global patterns of integrin expression, it is clear that the
Raf-MEK-ERK pathway can influence the activation state of
integrins by posttranslational mechanisms (39). These obser-
vations serve to illustrate that the activation of a single signal-
ing pathway can have profound effects on the expression
and/or activity of these key cell adhesion molecules.
There is ample evidence that the expression of avb3-integrin
on the surface of melanoma cells can promote increased cell
migration, invasion, and metastasis (79). These effects may be
a consequence of the ability of integrins to activate a variety of
cell-signaling pathways leading to inhibition of apoptosis (71,
79). Indeed, the ability of integrins to influence the activity of
Rho family GTPases, one of which, RhoC, has been reported
to confer metastatic potential on melanoma cells, may be im-
portant in this regard (17, 18). Despite this, it is unclear if
b3-integrin expression plays a role in the ability of Ras and Raf
to transform NIH 3T3 cells. It has previously been shown that
the capacity of human melanoma cells to form metastatic lung
tumors in an experimental system is dependent on the expres-
sion of avb3-integrin (50). Consequently, it is provocative that
forms of Ras that activate the Raf-MEK-ERK pathway in NIH
3T3 cells and thereby induce b3-integrin expression can elicit
metastatic lung tumors when injected into the tail vein of a
nude mouse. By contrast, forms of Ras that do not activate the
Raf-MEK-ERK pathway fail to elicit metastatic lung tumors,
although they retain the capacity to elicit local subcutaneous
tumors (82). The recent description of mice with compromised
b3-integrin expression or function will permit us to study the
role of b3-integrin in Ras-induced oncogenic transformation
and metastasis (38, 49).
Despite the reported role of avb3-integrin in the metastatic
behavior of human melanoma cells, it is unclear whether the
Raf-MEK-ERK signaling pathway influences b3-integrin ex-
pression in these cells. Although Ras mutations have been
found in approximately 30% of metastatic melanomas, there is
no apparent correlation reported between Ras activation, pro-
gression to a metastatic phenotype, and b3-integrin expression
(3, 7). Although Ras mutations are rarely detected in invasive
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glioblastoma cells, the frequent alterations or overexpression
of the receptors for EGF, PDGF, and fibroblast growth factor
may contribute to b3-integrin expression in a manner similar to
that described above in NIH 3T3 cells overexpressing the NGF
receptor (15, 28, 65). The use of pharmacological inhibitors of
signaling pathways should allow us to address the role of signal
pathways in the control of b3-integrin expression in a wider
variety of human cancer cell lines (20, 23, 25).
The expression of avb3-integrin on the surface of endothe-
lial cells is important in the process of angiogenesis and the
neovascularization of tumors. Although a role for the Raf-
MEK-ERK pathway in b3-integrin expression in endothelial
cells has not previously been described, we demonstrate that
Raf activation leads to elevated b3-integrin in TIME cells.
Further evidence that the Raf-MEK-ERK pathway plays an
important role in angiogenesis is suggested by the fact that
disruption of the B-Raf gene leads to a failure of endothelial
cell differentiation accompanied by increased apoptosis. Con-
sequently, B-Raf-nullizygous embryos die of vascular hemor-
rhage (86, 87). Although these data indicate an important role
for B-Raf in endothelial cell development, it is unlikely that
these effects are due solely to effects on b3-integrin expression,
since b3-integrin-nullizygous mice display normal vasculogen-
esis (38).
Although Raf activation in NIH 3T3 cells elicited increased
cell surface avb3-integrin expression, the overall consequences
of Raf transformation are a loss of focal adhesions and actin
stress fibers leading to decreased attachment to extracellular
matrix (70, 77). This somewhat paradoxical observation indi-
cates that the effects of Raf on cell adhesion are complex. On
the one hand, the induction of integrin expression might be
predicted to increase cell adhesion, a prediction borne out by
the fact that ectopic expression of human b3-integrin in NIH
3T3 promotes cell adhesion and spreading (data not shown).
However, presumably because of effects of Ras and Raf on
other components of the cell adhesion machinery, the pheno-
type of Raf-transformed cells is a loss of focal adhesions and
cell rounding. Indeed, this combination of biochemical events
seems more likely to promote cell migration as opposed to
stable ECM attachment, a hypothesis that would be consistent
with the role of b3-integrin in melanoma cell migration (50).
Although the effects of Ras on cell morphology are thought
to be mediated by Rho family GTPases (13, 91), it is clear that
the effects of Raf on the actin cytoskeleton and focal adhesions
in NIH 3T3 cells occur in the absence of any decrease in the
GTP loading of Rho, Rac, or cdc42 protein (M. Woodrow and
M. McMahon, unpublished observations). Moreover, the char-
acteristic morphology of Ras-transformed cells can be reverted
by pharmacological inhibition of MEK (35; M. McMahon,
unpublished observations). Taken together, these data argue
for an important role for the Raf-MEK-ERK pathway in Ras-
induced alterations in intracellular architecture. Indeed, in
MDCK cells the effects of Raf on the actin cytoskeleton and
cell migration occur in the absence of decreased GTP loading
of Rho family GTPases and appear to be associated with the
induced expression of Rnd3, an endogenous inhibitor of Rho
signaling (27, 34, 37, 62). Regardless of the mechanisms in-
volved, it is clear that activation of the ERK MAP kinase
pathway has pleiotropic effects on cell adhesion and migration
that may influence the invasion and metastasis of transformed
cells. It will be of considerable interest to reveal the full spec-
trum of molecular mechanisms underlying these observations
and to determine the extent to which they participate in the
aberrant behavior of human cancer cells.
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